[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100569168":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":23,"locations":33,"responsibleParty":50,"collaborators":53,"id":55,"slug":22,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":22,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":22,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":76,"overallStatus":36,"whyStopped":22,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Tianjin Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CXCR4 PET\u002FCT Imaging","EXPERIMENTAL","Intravenous injection of one dose of 2-5 mCi 68Ga\u002F18F-Pentixafor\u002FPentixather. Tracer doses of radiotracers will be used to image lesions by PET\u002FCT",[13],"Diagnostic Test: CXCR4 PET\u002FCT Imaging",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DIAGNOSTIC_TEST","Each subject receive a single intravenous injection of 68Ga\u002F18F-Pentixafor\u002FPentixather, and undergo PET\u002FCT imaging within the specificed time.",[9],[20,21],"68\u002F18F-Pentixafor","68\u002F18F-Pentixather",null,[24,29],{"name":25,"role":26,"phone":27,"phoneExt":22,"email":28},"Haonan Yu, MD","CONTACT","+8613821000597","dreamadam@126.com",{"name":30,"role":26,"phone":31,"phoneExt":22,"email":32},"Shaobo Yao, PhD","+8615122570279","yaoshaobo008@163.com",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Tianjin Medical University General Hospital","RECRUITING","Tianjin","Tianjin Municipality","300052","China","CN",{"type":43,"coordinates":44},"Point",[45,46],117.17667,39.14222,{"lat":46,"lon":45},[49],{"name":25,"role":26,"phone":27,"phoneExt":22,"email":28},{"type":51,"investigatorFullName":30,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":22,"oldOrganization":22},"PRINCIPAL_INVESTIGATOR","Prof.",[54],{"name":35,"class":6},"100569168",false,"NCT06690736","Chemokine Receptor 4 PET\u002FCT Imaging of CXCR4-Related Diseases","Inclusion Criteria:\n\n* suspected or confirmed untreated Lymphoproliferative and other CXCR4-related diseases patients\n* 18F-FDG PET\u002FCT within two weeks\n* signed written consent.\n\nExclusion Criteria:\n\n* pregnancy\n* breastfeeding\n* known allergy against Pentixafor",true,"ALL","18 Years","80 Years",{"count":65,"type":66},200,"ESTIMATED","INTERVENTIONAL",[69],"NA","To evaluate the potential usefulness of 68Ga\u002F18F-Pentixafor\u002FPentixather positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various CXCR4-related disease patients.",[72,73,74,75],"CXCR4-related Disease","Tumor","Positron Emission Tomography","Metastasis",[77,78,79,80],"PET\u002FCT","Chemokine receptor 4","Pentixafor","Pentixather","2025-02-07",{"date":83,"type":84},"2025-02-11","ACTUAL",{"date":86,"type":84},"2022-03-01",{"date":88,"type":66},"2027-10-01",{"name":5,"class":6},1]